Can you tell us a bit about your background?
I trained as a physician and scientist, having received both an MD and a PhD. I did my residency in pathology and about 11 years ago I decided to make the transition from academia to industry. Since then, most of my work has been focused on immunotherapy, which is a new and very exciting area of cancer research. Nine months ago I joined MedImmune, the global biologics arm of AstraZeneca, as the head of oncology development.